Biohaven Ltd. Form 8-K Summary
Business Context and Reporting Period
Date: August 26, 2026
Company: Biohaven Ltd. (BHVN)
Event: Entry into a Material Definitive Agreement (License Agreement) and Partial MIPA Assignment and Assumption Agreement with SK Biopharmaceuticals Co., Ltd. (SKBP).
Biohaven Bioscience Ireland Limited (BBIL), a wholly owned subsidiary of Biohaven, granted SKBP an exclusive, royalty-bearing, worldwide license to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), an investigational selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy.
Key Financial Metrics and Transaction Terms
Upfront Payment: $400 million total (non-creditable, non-refundable).
- $350 million payable at Closing.
- $50 million payable one year after Closing.
Development and Regulatory Milestones: Up to $150 million in one-time payments.
Royalties:
- U.S. net sales of opakalim and certain antiseizure products: Mid-teens to low twenties percent.
- Ex-U.S. net sales of opakalim and certain antiseizure products: Mid-single-digit percent.
- Additional royalties on net sales of other licensed products.
Assumed Obligations (MIPA Assignment): SKBP assumes obligations to Knopp Biosciences LLC totaling up to $245 million in potential milestones and mid-single-digit worldwide royalties on Kv7 products. These are separate from payments to Biohaven.
Cash Flow and Liquidity: The filing does not provide current cash flow, liquidity, or debt figures. The transaction is expected to provide significant near-term liquidity upon closing.
Material Changes and Operational Impact
- Strategic Shift: SKBP will assume responsibility for developing and commercializing opakalim in the United States, Europe, and Japan following regulatory approval.
- Continued Development: Biohaven will continue specified ongoing development and regulatory activities, including the RISE 2 and RISE 3 clinical studies and the preparation/filing of the new drug application (NDA) for opakalim.
- Cost Reimbursement: SKBP will reimburse specified pre-Closing program costs and fund certain development plan costs incurred by Biohaven.
- Restrictions: The agreement includes restrictions on both parties regarding competing Kv7 activators.
Guidance, Risks, and Contingencies
Closing Conditions: The transaction is subject to obtaining required antitrust clearances and the satisfaction or waiver of other customary closing conditions.
Termination Rights:
- SKBP may terminate the agreement for convenience upon specified prior written notice following Closing.
- Both parties have termination rights for uncured material breach or specified bankruptcy/insolvency events.
- Upon termination, licenses terminate for applicable products/territories, with limited rights to sell off existing inventory.
Risks: The filing does not provide specific forward-looking financial guidance or updated risk factors beyond the standard contingencies of regulatory approval and antitrust clearance.
Key Facts for Investor Verification
- Confirmation of antitrust clearance status and expected Closing date.
- Details of the "specified pre-Closing program costs" to be reimbursed by SKBP.
- Specific definitions of "mid-teens to low twenties" and "mid-single-digit" royalty tiers in the full agreement.
- Current status of the RISE 2 and RISE 3 clinical studies and the timeline for the NDA filing.
- Impact of the $245 million assumed MIPA obligations on SKBP's financial capacity to fund development.